Journals / Anestezi Dergisi / 2021 / Cilt: 29 - Sayı: 3

The Effect of Intraoperative Restrictive Fluid Therapy on Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy

Hipertermik İntraperitoneal Kemoterapi Yapılan Hastalarda İntraoperatif Restriktif Sıvı Tedavisinin Postoperatif Sonuçlar Üzerine Etkisi

Pages
196–201
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We concluded that intraoperative restrictive fluid therapy did not affect postoperative complications and mortality in HIPEC and SRS surgeries.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRC) are effective multimodal treatment options in patients with peritoneal carcinomatosis.
📊
Key Findings & Data:METHODS: Patients who underwent HIPEC and SRS in our clinic between 2014-2018 were included in the study.
💡
Conclusion & Impact:Conclusion: We concluded that intraoperative restrictive fluid therapy did not affect postoperative complications and mortality in HIPEC and SRS surgeries.
🔬Design:Research Article
📍Scope:2014-2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRC) are effective multimodal treatment options in patients with peritoneal carcinomatosis. Procedures are long-lasting operations with excessive blood and fluid loss. Intraoperative fluid management is very important because of major hemodynamic, respiratory and metabolic changes. This study aims to investigate the effect of intraoperative restrictive fluid therapy on postoperative outcome in patients undergoing HIPEC and SRS. METHODS: Patients who underwent HIPEC and SRS in our clinic between 2014-2018 were included in the study. The demographic, intraoperative and postoperative data of all patients were retrospectively analyzed. The patients who underwent restrictive fluid replacement were named Group R, and the group with liberal fluid replacement was named Group L. RESULTS: It was observed that the mean age was 54.6±11.4 years, the female gender was 60.5% and the malignancy originating from the gastrointestinal system was 76.3%. There was no effect of liberal and restrictive fluid treatments on postoperative minor and major complications, length of stay in hospital and intensive care, and mortality. Conclusion: We concluded that intraoperative restrictive fluid therapy did not affect postoperative complications and mortality in HIPEC and SRS surgeries.

Özet

Amaç: Hipertermik intraperitoneal kemoterapi (HİPEK) ve sitoredüktif cerrahi (SRC) peritoneal karsinomatozisli olgularda etkili multimodal tedavi seçeneklerindendir. Bu girişimler, kan ve sıvı kaybının fazla olduğu, uzun süren ameliyatlardır. Major hemodinamik, respiratuvar ve metabolik değişiklikler nedeniyle intraoperatif sıvı yönetimi oldukça önemlidir. Bu çalışma, HİPEK ve SRC yapılan hastalarda, intraoperatif restriktif sıvı tedavisinin postoperatif derlenme üzerine etkisini araştırmayı amaçlamıştır. Yöntem: Kliniğimizde 2014-2018 yılları arasında HİPEK ve SRC yapılan hastalar çalışmaya dâhil edildi. Retrospektif olarak tüm hastaların demografik, intraoperatif ve postoperatif verileri incelendi, restriktif sıvı replasmanı yapılan hastalara Grup R, liberal sıvı replasmanı yapılan gruba ise Grup L adı verildi. Bulgular: Hastaların yaş ortalamasının 54.6±11.4 yıl, kadın cinsiyetin %60.5 ve gastrointestinal sistem kaynaklı malignensinin de %76.3 olduğu gözlendi. Liberal ve restriktif sıvı tedavilerinin postoperatif minör ve major komplikasyonlarda, hastanede ve yoğun bakım kalış sürelerinde ve mortalite üzerine etkisi bulunmadı. Sonuç: HİPEK ve SRC ameliyatlarında intraoperatif restriktif sıvı tedavisinin postoperatif komplikasyonlar ve mortaliteyi etkilemediği sonucuna vardık.

🔖

Cite This Article

Karadeniz, Ü., Özay, H. Y., Bölükbaşı, D., Kemerci, P., Salman, N., Demir, A. (2022). The Effect of Intraoperative Restrictive Fluid Therapy on Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy. Anestezi Dergisi, Cilt: 29 - Sayı: 3, 196–201. https://ajindex.com/articles/440429

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol. 2010;15:36-43.
  2. Elias D, Honore C, Ciuchendea R, et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2008;95:1164-71.
  3. Balakrishnan KP, Survesan S. Anaesthetic management and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Indian J Anaesth. 2018;62:188- 96.
  4. Kajdi ME, Beck-Schimmer B, Held U, Kofmehl R, Lehmann K, Ganter MT. Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience. World J Surg Oncol. 2014;12:136.
  5. Liang Y, Wang S. The best anesthesia regimen for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Surg. 2015;19:103.
  6. Sheshadri DB, Chakravarthy MR. Anaesthetic considerations in the perioperative management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Indian J Surg Oncol. 2016;7:236-43.
  7. Shamavonian R, McLachlan R, Fisher OM, et al. The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2019;10:235-43.
  8. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155-62.
  9. Messina A, Robba C, Calabro L. et al. Perioperative liberal versus restrictive fluid strategies and postoperative outcomes: a systematic review and metanalysis on randomised-controlled trials in major abdominal elective surgery. Crit Care. 2021;25:205
  10. Myles PS, Bellomo R, Corcoran T, et al. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. N Engl J Med. 2018;378:2263-74. https://doi.org/10.105